The degradation mechanism is fundamentally superior to inhibition because it removes the entire protein, addressing both its enzymatic and scaffolding functions. This allows degraders to hit targets harder and more completely, suggesting they could become the dominant modality across oncology and other therapeutic areas.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.

Reversing the age of a mouse retina surprisingly caused the spontaneous clearance of protein buildups associated with macular degeneration. This suggests that restoring a cell's youthful epigenetic state also reactivates its innate ability to clean and repair itself, a promising sign for treating diseases like Alzheimer's.

While T-regs are most commonly associated with autoimmune conditions, Coya focuses on neurodegeneration. This strategy is based on their founder's research showing T-reg dysfunction is a major driver of diseases like ALS and FTD, applying a known biological mechanism to a novel, high-unmet-need therapeutic area.

Shifting focus from amyloid plaque, Dr. Francisco Gonzalez Lima's research suggests viewing Alzheimer's as a vascular disease rooted in mitochondrial dysfunction. This perspective opens new treatment avenues like low-dose methylene blue and photobiomodulation to improve mitochondrial function.

Voyager's CEO explains that amyloid and tau are not independent culprits in Alzheimer's. Tau clumps naturally with age in a small brain region. Amyloid accumulation then acts as a trigger, causing this "tau fire" to spread catastrophically, suggesting treatments may need to address both.